Olympus upgrades guidance following better-than-expected report

Japanese Olympus has closed this year's Q1 so well that the medtech firm, whose advisors include former Ambu CEO Lars Marcher, upgrades its guidance for the whole year.

Photo: Yuriko Nakao/Reuters/Ritzau Scanpix

Thursday morning, Japanese medical equipment manufacturer Olympus presented its first quarter financial result, which shows better sales than expected, which is also demonstrated in the firm's operating earnings.

Olympus, whose advisors include former Ambu CEO Lars Marcher, is upgrading its guidance for the whole year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs